التفاصيل البيبلوغرافية
| العنوان: |
Secondary debulking for ovarian carcinoma relapse: The R-R dilemma - is the prognosis different for residual or recurrent disease? |
| المؤلفون: |
Spiliotis, John D., Iavazzo, Christos, Kopanakis, Nikolaos D., Christopoulou, Athina |
| المصدر: |
Journal of the Turkish-German Gynecological Association; Dec2019, Vol. 20 Issue 4, p213-217, 5p, 2 Diagrams, 2 Charts |
| مصطلحات موضوعية: |
CANCER, CANCER chemotherapy, CANCER patients, COMPARATIVE studies, STATISTICAL correlation, DIAPHRAGM (Anatomy), DISEASES, MEDICAL records, MESENTERY, MORTALITY, MUSCLES, OVARIAN tumors, PELVIC floor, SURVIVAL analysis (Biometry), TIME, DISEASE relapse, RETROSPECTIVE studies, DESCRIPTIVE statistics, ACQUISITION of data methodology, CYTOREDUCTIVE surgery |
| مستخلص: |
Objective: To analyze the kind of ovarian cancer relapse by separating residual from recurrent disease and correlating them with patient survival. Material and Methods: This was a retrospective study of 200 women with ovarian carcinoma relapse between 2005 and 2017. Results: The main sites of residual disease included the great omentum, epiploic appendices, liver round ligament, gallbladder, and cervical/ vaginal stump. The median survival for women with residual disease treated with cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) + systemic chemotherapy was 38 months compared with the control group, which reached 23.8 months. The morbidity rates were 18% vs 7%, respectively, and the mortality rates were 2.5% vs 1.3%. The main sites of recurrent disease included the mesenterium, pelvic floor, diaphragm, and Glisson's capsule. Women with recurrent disease treated with CRS + HIPEC + systemic chemotherapy had median survival rates of 26 months vs 16 months in the control group. The morbidity rates were 22% vs 15%, respectively, and the mortality rates were 3.3% vs 0%. Conclusion: Patients undergoing secondary debulking plus HIPEC for ovarian carcinoma relapse have a different prognosis when compared with patients with residual and recurrent disease. A different prognosis is presented in women undergoing secondary debulking plus HIPEC for ovarian carcinoma relapse when comparing patients with residual and recurrent disease. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of the Turkish-German Gynecological Association is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder